- In November 2022, The Union Health Ministry of India announced the inclusion of coronary stents in the National List of Essential Medicines 2022. This decision was aimed at making coronary stents more affordable for the Indian population, thereby improving access to life-saving treatments for heart conditions and enhancing overall cardiovascular care across the country
- In May 2022, Medtronic received approval from the US FDA for the Onyx Frontier drug-eluting stent (DES), a significant advancement in cardiovascular treatment. This stent features a unique design to enhance the safety and effectiveness of heart procedures, offering improved clinical outcomes for patients suffering from coronary artery disease, with a focus on long-term performance
- In April 2022, Translumina, a prominent manufacturer of cardiovascular medical devices, launched its innovative VIVO ISAR dual drug polymer-free coated stent (DDCS) in international markets, including Europe. The stent offers improved drug delivery and vascular healing, providing an alternative to traditional drug-eluting stents and enhancing treatment options for patients undergoing interventional cardiology procedures globally
- In October 2020, Olympus, a leader in medical technologies, launched the HANAROSTENT Esophagus TTS self-expanding metal stents (SEMS) in the US. Manufactured by M.I. Tech and distributed exclusively through Olympus, these stents are designed for treating esophageal conditions, offering a reliable solution for physicians to manage obstructive and malignant conditions in the esophagus, improving patient care and quality of life
